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Osteonecrosis of the jaws (ONJ) is a rare but serious complication 
that has emerged recently in patients treated with bisphospho-
nates for bone metastases. The first case of bisphosphonate-
related ONJ was reported in 2003 (1). The incidence rates of 
bisphosphonate-induced ONJ ranged from 0% to 27.5%, with a 
mean incidence of 7% (2).
Recently, several case reports described the association 
between ONJ and denosumab, an antireceptor activator of 
nuclear factor kappa-B ligand monoclonal antibody approved 
for the prevention of skeletal-related events.
In November 2010, the European Medicine Agency issued 
safety alert about ONJ risk during sunitinib or bevacizumab 
treatment (3). This risk becomes amplified if the drug is added 
to bisphoshonate.
The pathogenesis of ONJ in patients treated with anti-angi-
ogenic drugs is still not completely elucidated; a soft tissue 
involvement through mucositis, stomatitis, and gingival inflam-
mation added to a decreased angiogenesis caused by these ther-
apies seems to impair host defenses to infection and increases 
the ONJ risk (4).
Regorafenib is a small-molecule multikinase inhibitor with 
an anti-angiogenic activity due to its dual targeted VEGFR2-
TIE2 tyrosine kinase inhibition. It is indicated for the treatment 
of patients with refractory metastatic colorectal cancer and 
advanced gastrointestinal stromal tumors (GIST) after progres-
sion to imatinib and sunitinib.
In our hospital, we followed a woman age 59  years with 
heavily pretreated metastatic colorectal cancer who pre-
sented a necrotic bone exposed to the oral environment in 
the upper jaw with pain and soft tissue inflammation after 
22 months of regorafenib treatment (160 mg orally once daily 
3 weeks on and 1 week off). The lesion persisted for up to 
eight weeks, and using the criteria of bisphosphonate-related 
ONJ (exposed bone for 6–8 weeks in absence of radiation to 
head and neck) (5), a clinical diagnosis of ONJ was made. A CT 
scan of maxillofacial region showed two clear necrotic bone 
areas extending beyond the alveolar bone area (Figure  1) to 
maxillary sinus, and so, according to ESMO guidelines, the 
stage of ONJ was III (5). The patient didn’t receive bisphospho-
nate anytime.
To the best of our knowledge, this is the first report describing 
ONJ in patients treated with regorafenib. We would like to alert 
the scientific community that even regorafenib could cause ONJ.
The increasing number of patients being treated with anti-
angiogenic agents underlines also the need for oral screening 
before treatment with these drugs, and further trials should 
investigate ONJ-preventive protocols similar to those already 
existing for patients treated with bisphosphonates.
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Figure  1. CT scan of maxillofacial region: two areas of osteolysis (6 mm and 
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